These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Plasma concentrations of unbound phenytoin in the management of epilepsy. Kilpatrick CJ; Wanwimolruk S; Wing LM Br J Clin Pharmacol; 1984 May; 17(5):539-46. PubMed ID: 6733002 [TBL] [Abstract][Full Text] [Related]
44. Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients. Neuvonen PJ; Bardy A; Lehtovaara R Br J Clin Pharmacol; 1979 Jul; 8(1):37-41. PubMed ID: 552295 [TBL] [Abstract][Full Text] [Related]
45. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. Chadwick D; Shaw MD; Foy P; Rawlins MD; Turnbull DM J Neurol Neurosurg Psychiatry; 1984 Jun; 47(6):642-4. PubMed ID: 6234378 [TBL] [Abstract][Full Text] [Related]
46. [EEG findings and phenytoin concentration in the serum of children with epilepsy]. Wässer S; Jalinski W; Meyer FP; Walther H Padiatr Grenzgeb; 1984; 23(2):87-92. PubMed ID: 6728491 [No Abstract] [Full Text] [Related]
48. Electroencephalography and phenytoin toxicity in mentally retarded epileptic patients. Iivanainen M; Viukari M; Seppäläinen AM; Helle EP J Neurol Neurosurg Psychiatry; 1978 Mar; 41(3):272-7. PubMed ID: 632825 [TBL] [Abstract][Full Text] [Related]
49. Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations. Shin JW; Chu K; Jung KH; Lee ST; Moon J; Lee SK Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1017-22. PubMed ID: 25295717 [TBL] [Abstract][Full Text] [Related]
51. [Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carbamazepine, pilot study]. Hernández R; Fernández Mde L; Miranda G; Suástegui R Rev Invest Clin; 2005; 57(4):522-31. PubMed ID: 16315636 [TBL] [Abstract][Full Text] [Related]
53. Serum-phenytoin, seizures, and electroencephalography. Iivanainen M; Viukari M Lancet; 1977 Apr; 1(8016):860-1. PubMed ID: 67371 [No Abstract] [Full Text] [Related]
54. Interference of oral phenytoin absorption by continuous nasogastric feedings. Bauer LA Neurology; 1982 May; 32(5):570-2. PubMed ID: 6803191 [TBL] [Abstract][Full Text] [Related]
55. [Clinical significance of blood levels of diphenylhydantoin orally administered to epileptic patients]. Ma ZZ Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Jun; 18(3):136-8. PubMed ID: 4053817 [No Abstract] [Full Text] [Related]
56. An interaction between cytostatic and anticonvulsant drugs. Neef C; de Voogd-van der Straaten I Clin Pharmacol Ther; 1988 Apr; 43(4):372-5. PubMed ID: 3128415 [TBL] [Abstract][Full Text] [Related]
57. Phenytoin: effective but insidious therapy for epilepsy in people with intellectual disability. Iivanainen M J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():24-31. PubMed ID: 10030428 [TBL] [Abstract][Full Text] [Related]
58. Control of epilepsy with a single daily dose of phenytoin sodium. Cocks DA; Critchley EM Br J Clin Pharmacol; 1975 Oct; 2(5):449-53. PubMed ID: 786358 [TBL] [Abstract][Full Text] [Related]
59. [Monitoring of plasma diphenylhydantoin levels in epileptic patients]. Lezama-Dávila CM; Olmos-García de Alba G; López-Anaya A; Valarezo-Crespo F Bol Med Hosp Infant Mex; 1983 May; 40(5):256-61. PubMed ID: 6871012 [No Abstract] [Full Text] [Related]
60. [Oral loading dose of phenytoin]. Galdames D; Aguilera L; Castillo S; Valenzuela M; Leyton S; Saavedra IN Rev Med Chil; 1988 Nov; 116(11):1162-6. PubMed ID: 3077203 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]